THC

Tenet Healthcare (THC), a hospital operator in the Medical-Hospital industry, has demonstrated a consistent pattern of beating earnings estimates. With an average surprise of 32.24% over the last two quarters and a positive Earnings ESP of +11.11%, analysts suggest the company is well-positioned to continue this streak in its next earnings report expected on October 29, 2026.

Tenet Healthcare is positioned as a likely earnings beat candidate for Q3 2026, with an Earnings ESP of +11.11% and a Zacks Rank #3 (Hold). The company is expected to report EPS of $4.60 (up 24.3% YoY) and revenues of $5.47 billion (up 3.5% YoY). Analysts have recently become more bullish, and the company has beaten consensus estimates in all four trailing quarters.

Tenet Healthcare (THC) closed down 1.17% to $269.13, underperforming the broader market. The hospital operator is expected to report earnings on October 29, 2026, with consensus estimates projecting EPS of $4.59 (24.05% growth) and revenue of $5.47 billion (3.34% growth).

The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 12.95, in line with industry averages. The Medical-Hospital industry ranks in the bottom 20% of all industries.

Tenet Healthcare (THC) is receiving significant investor attention. The hospital operator has returned +3.9% over the past month, outperforming the S&P 500's +0.7%.

The company is expected to post earnings of $4.59 per share for the current quarter (+24.1% YoY) with fiscal year earnings estimates of $21.04 (+25.4% YoY). However, Tenet received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the broader market. The stock is trading at a discount to peers with a Value Style Score of A.

Tenet Healthcare (THC) is featured as a stock to watch with a #3 (Hold) Zacks Rank and an A-rated VGM Score. The company demonstrates strong growth potential with a Growth Style Score of B and forecasted year-over-year earnings growth of 25.4% for the current fiscal year. One analyst revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $21.04 per share.

Tenet Healthcare (THC) closed at $275.13, up 1.3%, outperforming the S&P 500's 0.33% gain. The hospital operator is expected to report Q3 2026 earnings of $4.59 per share (up 24.05% YoY) with revenue of $5.47 billion (up 3.4% YoY).

Full-year estimates project $21.04 EPS and $22.2 billion revenue. THC holds a Zacks Rank #3 (Hold) with a Forward P/E of 12.91, trading in line with its industry average. The Medical-Hospital industry ranks 195th out of 250+ industries.

Tenet Healthcare closed at $263.78, up 1.23% and outpacing the S&P 500's 0.6% gain. The hospital operator is expected to report Q3 EPS of $4.59 (up 24.05% YoY) and revenue of $5.47 billion (up 3.4% YoY) on October 29, 2026. With a Zacks Rank of #3 (Hold) and Forward P/E of 12.39, THC trades in line with its industry average valuation.

Tenet Healthcare (THC) receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of B. The company benefits from attractive valuation metrics including a forward P/E ratio of 12.35 and a Value Style Score of A. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing $0.75 to $21.04 per share, and the company maintains an average earnings surprise of +22.7%.

Tenet Healthcare (THC) is receiving increased investor attention. The stock has underperformed the S&P 500 over the past month (-3.4% vs +1.4%).

While the company beat earnings and revenue estimates in recent quarters with strong EPS growth of +25.4% expected for the current fiscal year, the Zacks Rank #3 (Hold) rating suggests the stock may perform in line with the broader market in the near term. The company trades at a valuation discount to peers.

Tenet Healthcare stock rose 1.83% to $258.62, outperforming the S&P 500's 0.73% gain. The hospital operator is projected to report Q3 EPS of $4.59 (up 24.05% YoY) and revenue of $5.47 billion (up 3.4% YoY).

For the full year, earnings are forecast at $21.04 per share and revenue at $22.2 billion. THC holds a Zacks Rank #3 (Hold) with a Forward P/E of 12.07 and PEG ratio of 0.97.

Tenet Healthcare (THC) is accelerating share buybacks and raising 2026 free cash flow guidance to $1.825-$2.055 billion, supported by 27.1% year-over-year growth in operating cash flow to $2.2 billion. The company has $2.1 billion remaining in buyback authorization while continuing to invest in growth initiatives and managing debt obligations.

Tenet Healthcare (THC) is featured as a stock to watch with a #3 (Hold) Zacks Rank and an A VGM Score. The company shows strong growth prospects with forecasted year-over-year earnings growth of 25.4% for the current fiscal year, supported by three upward earnings estimate revisions in the last 60 days and an average earnings surprise of +22.7%.

Zacks Research Daily features analysis of 12 major stocks on October 20, 2026. SAP benefits from strong AI strategy and large deal bookings despite underperformance, while Accenture faces economic uncertainty but gains from enterprise transformation demand.

Moody's outperforms its industry with strong earnings, while Peoples Bancorp shows margin expansion but faces credit risks. Additional coverage includes Nucor, Tenet Healthcare, Toast, and other companies with mixed growth prospects.